HIV INFECTIONS

This study looked at two versions of the H1N1 flu vaccine in 306 adults with HIV. One vaccine had an extra ingredient (adjuvant) to boost the immune response, and the other did not. The goal was to see which vaccine was safer and worked better to protect against the flu. Particip…

This study tested whether an experimental HIV vaccine could prevent infection in over 5,400 sexually active adults in South Africa. Participants received either the vaccine or a placebo and were followed for up to 36 months. Unfortunately, the vaccine did not provide enough prote…

This early-stage study tested a new DNA-based HIV vaccine in 46 healthy adults without HIV. The vaccine was designed to train the immune system to recognize and fight HIV. Researchers checked for side effects and measured immune responses. The goal was to see if the vaccine is sa…

This early-stage study tested a new HIV vaccine in 34 healthy volunteers who did not have HIV. The goal was to see if the vaccine was safe and whether it triggered an immune response. Researchers used a chimpanzee virus to deliver the vaccine and a protein boost to try to teach t…

This study tested an experimental HIV vaccine in 132 healthy adults to see if it is safe and triggers an immune response. Participants received different combinations of the vaccine with or without adjuvants (substances that boost immune response). The goal was to gather early da…

This study tested a new HIV vaccine in 38 healthy infants who were exposed to HIV at birth but did not get the virus. The goal was to see if the vaccine is safe and helps the babies' immune systems fight HIV. The vaccine was given along with a special ingredient to boost its effe…

This early-stage study tested an experimental HIV vaccine called Trimer 4571 in 32 adults with HIV who were already on effective antiretroviral therapy (ART). The main goals were to see if the vaccine is safe and well-tolerated, and whether it can help the immune system produce b…

This study tested a new type of HIV vaccine made from a person's own white blood cells. The goal was to see if it is safe and can boost the immune system's ability to fight HIV. The study involved 40 adults with HIV who were already on effective antiretroviral therapy. Researcher…

This study tested an experimental HIV vaccine in 127 healthy adults who do not have HIV. The main goal was to see if the vaccine is safe and whether it triggers an immune response. Researchers used different combinations of vaccine ingredients and adjuvants (boosters) to find the…

This study tested two different schedules of an experimental HIV vaccine in 147 healthy adults at low risk for HIV. The goal was to see which schedule produced a stronger immune response and was safer. Volunteers received either three DNA vaccines followed by one booster, or two …

This study tested a vaccine called Triplex in 90 adults who have both HIV and cytomegalovirus (CMV). The goal was to see if the vaccine is safe and boosts the immune system's ability to fight CMV. Participants received either the vaccine or a placebo, and researchers monitored th…

This early-stage study tested an experimental HIV vaccine in 51 healthy adults to see if it is safe and can trigger an immune response. The vaccine is designed to train the body to make special antibodies that could block HIV. Researchers also tested different combinations of imm…

This early-stage study tested a new HIV vaccine in 24 healthy, HIV-negative adults to see if it is safe and can trigger an immune response. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus. The main goal was to check for side effects and measure…

This study tested three different ways to vaccinate people with HIV against hepatitis B, a virus that can cause serious liver damage. The standard vaccine often doesn't work as well in HIV patients, so researchers compared a double dose and skin injections to the usual method. Th…

This early-stage study tested two experimental HIV vaccines in 117 healthy, HIV-negative adults to see if they are safe and can trigger an immune response. Participants received several shots of the vaccines, which were designed to train the body to recognize HIV. The main goal w…

This study tested how well the Moderna COVID-19 vaccine worked in adults with a higher risk of severe illness, including people living with HIV. Over 14,000 participants in Eastern and Southern Africa received either two or three doses, depending on whether they had a prior COVID…

This study looked at how HIV drugs are processed in the body and how well patients take them. It included 35 adults newly starting HIV treatment. They took a combination of three drugs once daily, and a special pill bottle recorded each time it was opened. The goal was to see if …

This study tested whether giving interleukin-2 (IL-2) injections to HIV patients who had never taken antiretroviral drugs could help keep their CD4 cell counts high and delay the need for standard HIV therapy. The trial enrolled 130 adults with CD4 counts between 300 and 500. Res…

This study tested a single daily pill containing four HIV medicines in 129 teens and children who either had never been treated or had their virus already under control. Researchers checked how the drug moved through the body, its safety, and how well it kept the virus in check. …

This study tested a two-drug HIV pill (dolutegravir/lamivudine) in 32 teens aged 12-18 who had never taken HIV medication before. The goal was to see if this simpler daily pill could control the virus as well as standard three-drug regimens, while lowering the risk of long-term s…

This study looked at whether adding a drug called Interleukin-2 (IL-2) to standard HIV treatment could help patients whose current therapy was failing and who had very low CD4 counts (below 200). The goal was to see if more patients could raise their CD4 counts above 200 after 52…

This study tested the safety and tolerability of long-acting injectable HIV medications (cabotegravir and rilpivirine) in 168 children and teens whose HIV was already well-controlled. Participants received oral doses first, then switched to monthly or every-other-month injections…

This study tested two different combinations of HIV medications in 61 people who had not taken these types of drugs before. The goal was to see how well each combination could lower the amount of virus in the blood to very low levels after 16 weeks. Researchers also monitored saf…

This study tested a data-to-care approach to help people living with HIV in Ukraine who had missed medical visits. Researchers used health records to identify and contact these individuals, aiming to get them back into care and on antiretroviral therapy. The study involved 160 pa…

This study tested a counseling program for couples in Zambia to help pregnant women living with HIV stay healthy. Nearly 500 couples took part. The program focused on improving medication adherence and viral suppression through relationship strengthening.

This study tested a once-daily combination of three HIV drugs (tenofovir, emtricitabine, and efavirenz) in 70 adults with both HIV and tuberculosis who had not taken HIV medication before. The goal was to see if a simpler, once-daily pill routine could effectively control HIV whi…

This study tested a program called ENHANCE to help people with two or more long-term health problems like HIV, high blood pressure, diabetes, asthma, or depression. Over 1,800 adults aged 40 and older took part. Some clinics used a special decision-support tool and home visits fr…

This study tested two experimental oral medications (VH4004280 and VH4011499) in 44 adults with HIV who had never taken HIV drugs before. The goal was to see how well these capsid inhibitors lower the amount of virus in the blood over 10 days. Researchers also checked for side ef…

This study tested a new combination pill (polypill) that packs four heart failure medicines into one tablet. The goal was to see if it helps people take their medications more regularly compared to taking several separate pills. The study included 35 adults with heart failure, so…

This early-phase study tested a personalized vaccine for HIV made from each patient's own immune cells and virus. Eleven participants who had never taken HIV medication received the vaccine to see if it was safe and could lower their virus levels after a temporary break from trea…

This study tested a new approach to help people with substance use disorders take their daily HIV prevention pill (PrEP) consistently. Participants used a digital pill that tracks when it's swallowed, along with a smartphone app that provides reminders and support. The goal was t…

This study tested a combination of two drugs, peginterferon alfa-2a and ribavirin, as a second-line treatment for chronic hepatitis C in 17 people with HIV who did not respond to their first hepatitis C treatment. The goal was to see if this 48-week treatment could make the hepat…

This study tested a new type of counseling called BAPS to help smokers with HIV quit. 651 participants were split into two groups: one received standard smoking cessation counseling, the other received BAPS. The goal was to see which approach led to more people quitting smoking b…

This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV. 140 participants received either alendronate or a placebo, along with calcium and vitamin D, for 2 years. The main goal was to measure changes in bone density in the …

This study looked at 66 HIV-positive adults who switched from a standard three-drug treatment to either a two-drug or a three-drug regimen. The goal was to see how these changes affected markers of inflammation and immune system balance. All participants had undetectable virus le…

This study looked at whether adults aged 50 and older living with HIV could safely switch from a three-drug pill to a simpler two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch and were f…

This study tested whether adding an extra HIV drug called enfuvirtide to standard therapy for 6 months helps people with very advanced HIV infection. The 195 participants had dangerously low CD4 counts (a measure of immune health) and had never taken HIV drugs before. The goal wa…

This study tested a counseling program called the Friendship Bench for 106 teens aged 13-18 living with HIV and depression. The goal was to see if the program is feasible and acceptable, and whether it can reduce depression symptoms and improve engagement in HIV care. The study c…

This study tested a new way to manage high blood pressure and heart disease risk in people living with HIV in Botswana. Over 4,600 adults on HIV treatment joined the program, which added blood pressure checks and medication to their regular HIV clinic visits. The goal was to see …

This early-stage study tested a new injectable drug, Lipovirtide, in 24 people with HIV who were not taking any other HIV medications. The main goal was to check if the drug is safe and how the body processes it. Researchers also looked at whether it could lower the amount of vir…

This study looked at 558 people with HIV whose first treatment was no longer controlling the virus. Researchers compared two different second-line drug combinations: one with standard HIV drugs plus a booster, and another with a newer integrase inhibitor. After 48 weeks, both app…

This study tested whether adding a powerful HIV drug called FUZEON® to standard antiretroviral therapy could help people with HIV who have a rare brain infection called PML. PML is caused by the JC virus and usually affects people with weak immune systems. The study included 30 a…

This study looked at how safe and effective a hepatitis A vaccine is for people with HIV, aged 1 to 50. About 392 participants received two vaccine doses six months apart. Researchers checked their blood for antibodies and tracked any side effects for a month after each dose. The…

This study offers children and teens with HIV continued access to dolutegravir, a powerful HIV medication, after they finished earlier studies. About 100 participants who tolerated the drug well will receive age-appropriate doses every 12 weeks until the drug is locally approved …

This study tested a drug called alirocumab in 118 adults with HIV who were at risk for heart disease. The goal was to see if the drug could reduce inflammation in the arteries and improve blood vessel function. Participants received either the drug or a placebo for about a year, …

This study tested whether people with well-controlled HIV could safely take their antiretroviral medication for 4 consecutive days each week, followed by 3 days off, instead of taking it every day. 640 adults with stable HIV participated. After 48 weeks, the 4-day schedule was fo…

This study tested an enhanced football-based program for over 2,000 teenage girls in Zambia. The program added HIV self-testing, birth control information, and access to a nurse to encourage more teens to get tested for HIV and use prevention services. The goal was to help those …

This study tested whether a mobile health unit that offers addiction treatment, HIV care, and prevention in one place can help people who inject drugs get the care they need. 447 adults with opioid use disorder and recent injection drug use took part. The goal was to see if this …

This study tested an oral drug called selgantolimod in 29 adults who have both chronic hepatitis B and HIV and have been on stable antiviral therapy for at least 5 years. The goal was to see if the drug is safe and can lower hepatitis B surface antigen (HBsAg) levels in the blood…

This study tested a short video shown in HIV clinic waiting rooms to help patients start and stay on antiretroviral therapy. Over 4,000 people from clinics serving mostly African American and Hispanic communities took part. The video aimed to improve medication adherence, keep pa…

This study looked at whether people with HIV who were already on a successful treatment regimen including enfuvirtide could safely switch to a different drug, raltegravir, without the virus rebounding. 170 adults with suppressed HIV (below 400 copies/mL) were randomly assigned to…

This study tested whether HIV patients with long-term viral suppression could switch to a single drug (darunavir/r) instead of the standard two-drug regimen. 225 participants were followed for 48 weeks to see if the single drug could keep the virus undetectable. The goal was to s…

This early-stage study tested an experimental antibody called VRC01 in 24 adults with very recent HIV infection. The goal was to see if it is safe and can lower the amount of virus in the blood, either alone or with standard HIV medications. The study found that VRC01 was general…

This study tested two statins, rosuvastatin and pravastatin, in 86 people with HIV who had high cholesterol and were taking antiretroviral drugs. The goal was to see which drug lowers LDL (bad) cholesterol more safely and effectively over 45 days. Results help doctors choose the …

This early-stage study tested a new experimental HIV drug called VH4524184 in 84 healthy adults to see if it is safe and how the body processes it. The study also checked whether the drug affects a key liver enzyme that can change how other medicines work. Because HIV requires li…

This early-stage study tested a single injection of a new drug called lipovirtide in 46 adults with HIV who had never taken antiviral medicine. The main goal was to see if the drug is safe and how the body processes it. This is a first step toward possibly finding a new treatment…

This study tested whether adding the drug maraviroc to standard HIV treatment for 24 weeks could improve immune function in people whose CD4 counts stayed low even though their HIV was well-controlled. The trial included 60 HIV-positive adults with CD4 counts below 350 and little…

This study looked at whether people with HIV can safely donate a kidney to another person with HIV. Three HIV-positive donors were followed to track any health problems after donation. The goal was to see if this type of donation is safe and could help more people get transplants…

This study tested whether adding patient incentives to integrated care centers helps more people with HIV achieve viral suppression. Over 2,300 people who inject drugs or are men who have sex with men in India took part. The goal was to find cost-effective ways to improve HIV tre…

This study tested a program where Black and Hispanic young adults (ages 18-29) with HIV used video calls to talk with trained HIV+ peer coaches. The goal was to help them take their HIV medications more consistently and lower their viral load. The program used motivational and co…

This study looked back at medical records of 800 people with HIV to compare two different drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus under control over 48 weeks. The study focused on real-…

This study looked at how well new rapid HIV tests work compared to standard lab tests. The goal was to see if faster results help more people start HIV treatment or prevention medicine during the same visit. 224 adults at high risk for HIV in Baltimore took part. The findings cou…

This study tested a strategy of using rapid point-of-care tests to screen pregnant women for sexually transmitted infections (STIs) like chlamydia, gonorrhea, and syphilis during routine antenatal visits in Zimbabwe. Over 1,000 women participated to see if immediate testing and t…

This study tested a fast, simple test that checks for both HIV and syphilis at the same time in pregnant women in Guatemala. The goal was to see if using this test would help more women get screened and treated during pregnancy, which could prevent passing these infections to the…

This large study tested whether a long-acting injectable drug (cabotegravir) could prevent HIV infection better than daily oral pills in men and transgender women who have sex with men and are at high risk. Over 4,500 participants received either the injection every 8 weeks or a …

This project aimed to make it easier for young women in Kenya to get HIV prevention services, including PrEP pills, right at their family planning clinic. Over 25,000 women took part. The goal was to see if offering these services together helps more women get screened for HIV ri…

This study tested whether a GPS-based mobile app, financial incentives, and peer mentors could help men who have sex with men and transgender women leaving jail get HIV prevention services like PrEP and testing. 233 participants were split into two groups: one got routine case ma…

This early-stage study tested a vaginal ring that slowly releases the HIV drug tenofovir over 90 days. The goal was to see if the ring is safe and delivers enough drug to prevent HIV. 49 healthy women took part, and researchers measured drug levels in blood, vaginal fluid, and ti…

This study tested whether having a peer (a friend or community member) talk to African American and Hispanic/Latino men who have sex with men could help them start taking PrEP, a daily pill that prevents HIV. About 98 men who were not on PrEP took part. The goal was to see if thi…

This study tested a toolkit designed to help African American women at risk for HIV get PrEP, a daily pill that prevents HIV. The toolkit was used in two clinics in Mississippi and also addressed intimate partner violence, which can make it harder for women to focus on HIV preven…

This study tested whether barbershops are a good place to offer HIV prevention programs for heterosexual men in the Kalangala Islands, Uganda. About 250 men took part to see if they would join and like the program. The goal was to find new ways to reach men who are at risk for HI…

This study tested a simple checklist for hospital staff to help people who inject drugs get HIV prevention medicine (PrEP) and addiction treatment. Researchers worked with 60 HIV-negative adults with opioid use disorder at a hospital in Alabama. The goal was to see if this approa…

This study looked at two different methods for giving cabotegravir PrEP (an HIV prevention shot) to HIV-negative men who have sex with men and transgender men aged 18 and older. About 287 participants received the medication either after a one-month oral lead-in or directly as in…

This study tested a digital program to help male couples create personalized plans to prevent HIV and other sexually transmitted infections. Over 770 couples joined, and researchers tracked their infection rates, communication, and commitment over 16 months. The goal was to see i…

This study looked at how safe and effective a daily HIV prevention pill (TAF-FTC) is in 54 Kenyan women at risk of HIV. Participants took different numbers of pills each week to see how drug levels build up in the blood. The goal is to help doctors better understand how well the …

This study tested different support strategies to help women at high risk for HIV in South Africa keep taking their daily prevention pill (PrEP). 304 female sex workers and young women were given a combination of case management, food vouchers, peer support, or community pick-up …

This study tested a pop-up clinic inside a van to help women who inject drugs and exchange sex get HIV prevention medicine (PrEP), treatment for opioid use disorder, and quick testing for sexually transmitted infections. Fifty women took part in Seattle. The goal was to see if th…

This study looked at how to best give HIV prevention shots (called CAB PrEP) to Black cis and transgender women in the US. Researchers tested different ways to offer the shots in clinics and asked both patients and staff what worked well and what didn't. The goal was to make it e…

This study aimed to see how acceptable PrEP (a daily pill to prevent HIV) is among men who have sex with men and transgender individuals who agreed to HIV and STI testing through community outreach, both online and in person. Researchers recruited 209 participants from a geolocat…

This study tested a program called Malkia Klabu ("Queen Club") in Tanzania. It trained local drug shops to be more welcoming to adolescent girls and young women, so they could easily get HIV prevention services and contraception. The goal was to see if this approach increased HIV…

This study tested a new way to help Latino men who have sex with men start taking PrEP, a daily pill that prevents HIV. Researchers trained siblings to have supportive conversations about PrEP. The goal was to see if this approach increases PrEP use compared to siblings talking a…

This study tested a filmed soap opera (telenovela) designed to help Latinas in North Carolina learn about and practice HIV prevention. About 95 women watched the online episodes and reported changes in condom use, HIV testing, and awareness of PrEP medication. The goal was to see…

This study tested whether trained peer navigators (women with similar experiences) could help women involved in the criminal justice system access HIV prevention medication called PrEP. The goal was to reduce stigma and improve health. Thirty women aged 18-49 in San Francisco pro…

This study tested a two-drug HIV treatment (lopinavir/ritonavir) in 105 pregnant women with HIV to see if it could prevent mother-to-child transmission while reducing side effects from standard three-drug combos. The goal was to keep the mother's virus level low before delivery. …

This study tested whether giving HIV-negative pregnant women a home HIV test kit for their male partners would increase testing rates compared to just inviting partners to clinic testing. Researchers worked with 200 pregnant women in Malawi, randomly assigning them to either give…

This study looked at whether Tai Chi, a gentle mind-body exercise, can improve quality of life for adults living with both HIV and chronic pain. Thirty-six participants aged 45 and older took part in a 10-week Tai Chi program. The goal was to see if the program was feasible and a…

This study tested a training program for people living with HIV to help them become more involved in their own care. The program, led by psychologists, aimed to improve emotional, mental, and behavioral engagement with treatment. 75 participants completed the program, and researc…

This study tested whether eating golden rice cookies with piper crocatum daily for 28 days could lower fasting blood sugar and improve quality of life in 102 adults with HIV who also have high blood sugar. Participants either received the special cookies or plain control cookies.…

This study looked at whether medical cannabis can reduce nerve pain and inflammation in people living with HIV. 35 participants used different ratios of THC and CBD over 14 weeks. Researchers measured changes in pain severity and blood markers of inflammation. The goal was to see…

This study tested whether the experimental HIV drug ulonivirine (MK-8507) causes changes in heart rhythm. 62 healthy adults received the drug or a placebo, and their heart activity was measured. The goal was to gather safety information, not to treat any disease.

This study tested a method called public deliberation, where community members learn about a topic, hear different viewpoints, and discuss ethical issues together. The goal was to see if this approach could help improve how teens give consent for HIV prevention research, especial…

This study tested a special digital pill that sends a signal when taken, along with a phone app, to help HIV-negative men who have sex with men and struggle with substance use stick to their daily HIV prevention medication (PrEP). Forty participants took the digital pill for 60 d…

This study aimed to find out how many people held at the Nîmes administrative detention center have HIV, hepatitis B, or hepatitis C. Researchers used rapid tests to get results quickly, since many detainees leave before standard lab results come back. A total of 350 detainees to…

This study tested two different long-acting versions of the HIV drug cabotegravir in 56 healthy adults. The goal was to see how safe they are and how the body processes them, not to treat HIV. Participants received a single injection, and researchers measured drug levels and side…

This early study tested whether a single dose of the cancer drug pembrolizumab is safe for people with well-controlled HIV. Researchers wanted to see if the drug could help reveal HIV that may be hiding in the brain. Thirteen adults with HIV took part, and the main goal was to ch…

This study followed 200 transgender and non-binary people living with HIV across Europe for 18 months. Researchers collected data from routine blood tests to see how well HIV treatment was working. The goal was to learn more about this group's health needs and help design better …

This study looked at whether offering rapid HIV tests in community settings is practical for men who have sex with men (MSM). Researchers worked with French and Canadian teams to test the approach with 357 participants. The goal was to understand the benefits and challenges, not …

This study looked at how HIV and tuberculosis medications are processed in the bodies of pregnant women and new mothers. Over 1,500 participants provided blood samples to measure drug levels during pregnancy and after childbirth. The goal was to find the right doses to keep both …

This study looked for undiagnosed HIV in 300 hospital patients who had signs or behaviors that put them at risk. Researchers used a quick finger-prick test at the bedside. The goal was to see how many people had HIV without knowing it, so they could get care sooner.

This study tested a digital, community-led program in rural Appalachia and the Midwest to help people reduce risks from opioid use and prevent HIV and hepatitis C. Over 500 adults took part, with half currently or previously using illicit substances. The program encouraged HIV/HC…

This study looked at whether people with HIV who regularly use cannabis can stop for 28 days and if that break improves their mood, pain, sleep, and HIV control. Twenty-five participants were given money rewards for staying cannabis-free, confirmed by urine tests. The goal was to…

This study looked at how pregnancy changes the levels of the HIV drug doravirine in the body. Seven pregnant women living with HIV took a single dose of doravirine during their second and third trimesters, and again after giving birth. The goal was to find the right dose for preg…

This study looked at how a new HIV drug, VH4524184, is absorbed by the body and how it interacts with other common medicines. It involved 126 healthy adults aged 18 to 60. The goal was to gather information, not to treat HIV, so participants did not have HIV. Results will help gu…

This study worked with 51 healthcare professionals at primary care clinics to find ways to reduce stigma toward people who use drugs, especially in HIV prevention and care. Researchers tested a program that combined staff education and policy changes to see if it could make provi…

This study tested a training program for family medicine doctors in Alabama. The goal was to help them feel more comfortable talking about sexual health and HIV prevention, including PrEP, with teenage girls and young women. 46 doctors completed surveys before and after training …

This study looked back at 30 people with HIV who had already received CAR T-cell therapy for certain blood cancers. Researchers collected standard medical data to see what side effects occurred and how the immune system changed over time. The goal was to learn more about safety a…

This study looked at 99 heterosexual men — some living with HIV on effective treatment, others healthy — to compare their quality of life, depression levels, and sexual function. Participants filled out questionnaires about their well-being, mood, and sexual health. The goal was …

This study looked at how a single dose of THC (the active ingredient in cannabis) changes immune-related genes and proteins in the blood. Researchers compared 56 healthy volunteers—some with HIV, some without—to see if their immune systems responded differently. The goal was to u…

This study looked at how regular cannabis use affects brain health and immune function in people with HIV and those without. Researchers used brain scans and thinking tests to compare 80 cannabis users and 80 non-users in each group. The goal was to understand how cannabis and HI…

This study tested a program that brings in family and friends to support people receiving methadone treatment for opioid addiction in Tanzania. The goal was to see if this social support approach is acceptable and practical. About 20 people on methadone and up to 60 of their supp…

This study tested different methods of delivering HIV testing and counseling to young male couples (ages 15-24). Researchers wanted to see which approach helped partners communicate better and reduce risky sexual behavior. 71 couples participated, and the study focused on improvi…

This study looked at whether community health workers visiting pregnant women at home in rural South Africa can improve health for both mothers and children. About 1,490 women took part, with some areas getting the home-visit program and others not. The program aimed to help with…

This study followed 603 pregnant women in South Africa to see if infections in the genital tract are linked to giving birth earlier. Researchers collected swabs to test for various infections and analyzed the vaginal microbiome. The goal was to understand which germs or combinati…

This completed study looked at how HIV and tuberculosis medications behave in the bodies of pregnant women and new mothers. Researchers measured drug levels in 205 women during pregnancy and after delivery to find the right doses. The goal was to make sure both mother and baby ge…

This study involved 90 adults with HIV who were already prescribed a long-acting injectable medication. Researchers wanted to see if patients preferred getting their shots at a regular HIV clinic or at a multi-purpose day hospital. Participants filled out questionnaires about how…

This study looked at how well COVID-19 vaccines work in people with HIV compared to those without HIV. Researchers followed 75 adults aged 55 and older for 48 weeks, taking blood and saliva samples to measure immune responses. The goal was to understand if the vaccine works diffe…

This study tested a new rapid HIV test for babies and young children in Zambia. The goal was to see if faster diagnosis helps more infected infants start antiretroviral therapy (ART) sooner. Over 1,600 HIV-exposed infants took part, and the results showed improved treatment initi…

This study follows 179 volunteers who received an experimental HIV vaccine about 10 years ago. Researchers want to see if the vaccine's immune effects still last and how it has affected the virus in their bodies. No new treatment is given; this is just an observation to gather lo…

This study looked at 460 people with HIV who had cancer to find out which cancers are most common and why some choose to join cancer clinical trials. Researchers collected information on cancer types and offered optional quality-of-life surveys. The goal was to better understand …

This study looked at how women who inject drugs feel about a long-acting injectable HIV prevention medication called CAB-LA. Researchers wanted to understand what helps or hinders their decision to use it, and how it compares to daily pills. The goal is to design better programs …

This study looked at 248 adults in France who take PrEP (a pill to prevent HIV). Researchers compared people who had been on PrEP for over a year to those on it for less than a year, checking for sexually transmitted infections (STIs) and risky sexual behaviors. The goal was to u…

This study aimed to understand how aging affects specific enzymes in the body that are needed to activate a common HIV prevention and treatment drug. Researchers collected blood and colon tissue samples from 21 adults of different ages, some taking the drug and some not, to measu…